ArticleFrontiers in immunology2020
Haplotype-Based Analysis of
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Granulocyte colony-stimulating factor priming improves embryos and pregnancy rate in patients with poor ovarian reserve: a randomized controlled trial.Reproductive biology and endocrinology : RB&E · 2023Trial
- Two-way tuning of the decidual natural killer cells and recurrent pregnancy loss.Scientific reports · 2026Article
- Parental KIR/HLA-C Profiles and Reproductive Failure: A Phenotype-Stratified Retrospective Analysis of Couples With Fertility Disorders.Obstetrics and gynecology international · 2026Article
- Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.PloS one · 2026Article
- Full-resolution HLA and KIR gene annotations for human genome assemblies.Genome research · 2024Article
- Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed/refractory neuroblastomas post autologous hematopoietic stem cell transplantation.Scientific reports · 2024Article
- HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma.Immunogenetics · 2024Article
- Centromeric AA motif in KIR as an optimal surrogate marker for precision definition of alloimmune reproductive failure.Scientific reports · 2024Observational
- Full resolution HLA and KIR genes annotation for human genome assemblies.bioRxiv : the preprint server for biology · 2024Article
- Article
- HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis.Frontiers in immunology · 2024Article
- Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.Molecular cancer · 2023Article
- KIR Allelic Variation and the Remission of Atopic Dermatitis Over Time.ImmunoHorizons · 2023Article
- Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.Frontiers in immunology · 2023Article
- TheFrontiers in immunology · 2023Article
- Characterization of KIRHLA · 2022Article
- Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes.HLA · 2022Article
- Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health.The journal of allergy and clinical immunology. In practice · 2022Article
- Comparative genetics of KIR haplotype diversity in humans and rhesus macaques: the balancing act.Immunogenetics · 2022Article
- A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibitory Killer-cell Immunoglobulin-like Receptors (KIR) specific for HLA class I molecules enable human natural killer cells to monitor altered antigen presentation in pathogen-infected and tumor cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.